Show Summary Details
Page of

Parathyroid hormone 

Parathyroid hormone
Parathyroid hormone

Richard W. Keen

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 January 2021

Parathyroid hormone (PTH) is the first ‘anabolic’ treatment available for the management of osteoporosis.

PTH is given as a daily subcutaneous injection.

Teriparatide (recombinant human PTH 1–34) 20 μg/day has been demonstrated to reduce the risk of vertebral and non-vertebral fractures, whereas Preotact® (recombinant human PTH 1–84) 100 μg/day has only been demonstrated to reduce the risk of vertebral fractures.

PTH therapy stimulates bone turnover, with a predominant effect on osteoblast function. This causes a significant increase in bone formation, leading to gains in bone mass, improvements in skeletal microarchitecture, and increases in cortical thickness.

Treatment with PTH is generally safe and well tolerated.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.